REVIEW PAPER
The quality of life of people with rare inborn errors of metabolism and their caregivers
Publication date: 2018-06-07
Pediatr Pol 2018;93(2):148-152
KEYWORDS
ABSTRACT
A child’s disease, especially inborn and chronic disease, is a challenge for parents and it affects the quality of life of all family members. The paper presents research on attitudes towards the diagnosis and therapy in families of children with inborn errors of metabolism. The paper also describes problems and emotions that parents and patients have in their everyday life, as well as the priorities and needs of the family at particular stages of the child’s development. The analysis of attitudes towards the diagnosis and therapy makes it possible to develop methods of effective interventions that facilitate the implementation of therapeutic recommendations. The identification of factors affecting the quality of life in families of children with rare inborn errors of metabolism may contribute towards the development of programs to improve the quality of life of care-givers and patients with inborn diseases requiring chronic therapy.
REFERENCES (51)
1.
Rodwell C, Aymé S (red.). 2014 Report on the State of the Art of Rare Disease Activities in Europe – Poland. EUCERD. Dostęp: http://www.eucerd.eu/upload/fi....
3.
Zespół ds. Chorób Rzadkich. Narodowy Plan dla Chorób Rzadkich – mapa drogowa. 2012. Dostęp: http://www.rzadkiechoroby.pl/m... (19.11.2015).
4.
What is a rare disease? Eurordis – Rare Diseases Europe. Dostęp: http://www.eurordis.org/sites/... /Fact_Sheet_RD.pdf.
5.
European Medicines Agency. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. Dostęp: http://www.ema.europa.eu/docs/... Scientific_guideline/2009/09/WC500003637.pdf (22.04.2017).
7.
Program badań przesiewowych noworodków w Polsce na lata 2015-2018. Dostęp: http://www.mz.gov.pl/zdrowie-i... (19.03.2017).
8.
Mak CM, Lee HC, Chan AY i wsp. Inborn errors of metabolism and expanded newborn screening: review and update. Crit Rev Clin Lab Sci 2013; 50: 142-162.
9.
Cederbaum S, Lemons C, Batshaw ML. Alternative pathway or diversion therapy for urea cycle disorders now and in the future. Mol Genet Metab 2010; 100: 219-220.
10.
de Ru MH, Bouwman MG, Wijburg FA i wsp. Experiences of parents and patients with the timing of Mucopolysaccharidosis type I (MPS I) diagnoses and its relevance to the ethical debate on newborn screening. Mol Genet Metab 2012; 107: 501-507.
11.
Khangura SD, Tingley K, Chakraborty P i wsp. Child and family experiences with inborn errors of metabolism: a qualitative interview study with representatives of patient groups. J Inherit Metab Dis 2016; 39: 139-147.
12.
Botkin JR, Teutsch SM, Kaye CI i wsp. Outcomes of interest in evidence-based evaluations of genetic tests. Genet Med 2010; 12: 228-235.
13.
Groft SC, de la Paz MP. Rare diseases – avoiding misperceptions and establishing realities: the need for reliable epidemiological data. Adv Exp Med Biol 2010; 686: 3-14.
14.
Pianta RC, Marvin RS, Britner PA i wsp. Mothers’ resolution of their children’s diagnosis: Organized patterns of caregiving representations. Infant Ment Health J 1996; 17: 239-256.
15.
Lord B, Wastell C, Ungerer J. Parent reactions to childhood Phenylketonuria. Fam Syst Health 2005; 23: 204-219.
16.
Lord B, Ungerer J, Wastell C. Implications of resolving the diagnosis of PKU for parents and children. J Pediatr Psychol 2008; 33: 855-866.
17.
Witalis E, Mikoluc B, Motkowski R i wsp. Phenylketonuria patients’ and their parents’ acceptance of the disease: multi-centre study. Qual Life Res 2016; 25: 2967-2975.
18.
Witalis E, Mikołuc B, Motkowski R i wsp. Phenylketonuria patients’ and their parents’ knowledge and attitudes to the daily diet – multi-centre study. Nutr Metab 2017; 14: 57.
19.
van Spronsen FJ, Bélanger-Quintana A. Outcomes of phenylketonuria with elevance to followup. JIMD Re 2011; 1: 49-55.
20.
Feillet F, MacDonald A, Hartung Perron D i wsp. Outcomes beyond phenylalanine: an international perspective. Mol Genet Metab 2010; 99: 79-85.
21.
Levy HL, Waisbren SE. PKU in adolescents: rationale and psychosocial factors in diet continuation. Acta Paediatr 1994; 407: 92-97.
22.
Hatzmann J, Heymans HS, Ferrer-i-Carbonell A i wsp. Hidden consequences of success in pediatrics: parental health-related quality of life-results from the care project. Pediatrics 2008; 122: 1030-1038.
23.
ten Hoedt AE, Maurice-Stam H, Boelen CC i wsp. Parenting a child with phenylketonuria or galactosemia: implications for health-related quality of life. J Inherit Metab Dis 2011; 34: 391-398.
24.
Yamaguchi K, Wakimizu R, Kubota M. Difficulties in Daily Life and Associated Factors, and QoL of Children with Inherited Metabolic Disease and Their Parents in Japan: A Literature Review. JIMD Rep 2017; 33: 1–10.
25.
Di Ciommo V, Forcella E, Cotugno G. Living with phenylketonuria from the point of view of children, adolescents, and young adults: a qualitative study. J Dev Behav Pediatr 2012; 33: 229-235.
26.
Hatzmann J, Valstar MJ, Bosch AM i wsp. Predicting health-related quality of life of parents of children with inherited metabolic diseases. Acta Paediatr 2009; 98: 1205-1210.
27.
Shaji Thomas D, Mohd Wali Shakman L, Saraswathy K i wsp. Parenting a child with metabolic diseases: Impact on health related quality of life of parents. Diabetes Metab Syndr 2017; 11: 25-29.
28.
Packman W, Henderson SL, Mehta I i wsp. Psychosocial issues in families affected by maple syrup urine disease. J Genet Couns 2007; 16: 799-809.
29.
Fabre A, Baumstarck K, Cano A i wsp. Assessment of quality of life of the children and parents affected by inborn errors of metabolism with restricted diet: preliminary results of a cross-sectional study. Health Qual Life Outcomes 2013; 11: 158.
30.
Eiser C, Varni JW. Health-related quality of life and symptom reporting: similarities and differences between children and their parents. Eur J Pediatr 2013; 172: 1299-1304.
31.
Upton P, Lawford J, Eiser C. Parent–child agreement across child health-related quality of life instruments: a review of the literature. Qual Life Res 2008; 17: 895-913.
32.
Casier A, Goubert L, Gebhardt WA i wsp. Acceptance, wellbeing and goals in adolescents with chronic illness: a daily process analysis. Psychology Health 2013; 28: 1337-1351.
33.
Roberts RM, Muller T, Sweeney A i wsp. Relationships Between Childhood Experiences and Adulthood Outcomes in Women with PKU: A Qualitative Analysis. JIMD Rep 2017; 32: 41-49.
34.
Kestilä L, Koskinen S, Martelin T i wsp. Determinants of health in early adulthood: what is the role of parental education, childhood adversities and own education? Eur J Public Health 2005; 16: 305-314.
35.
Crone MR, van Spronsen FJ, Oudshoorn K i wsp. Behavioural factors related to metabolic control in patients with phenylketonuria. J Inherit Metab Dis 2005; 28: 627-637.
36.
Jaser SS, Whittemore R, Ambrosino JM i wsp. Mediators of depressive symptoms in children with type 1 diabetes and their mothers. J Pediatr Psychol 2008; 33: 509-519.
37.
Jaser SS, Whittemore R, Ambrosino JM i wsp. Coping and Psychosocial Adjustment in Mothers of Young Children With Type 1. Diabetes Child Health Care 2009; 38: 91-106.
38.
Lee P. Growing older: The adult metabolic clinic. J Inherit Metab Dis 2002; 25: 252-260.
39.
Simon E, Schwarz M, Roos J i wsp. Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual Life Outcomes 2008; 6: 25.
40.
Weglage J, Funders B, Wilken B i wsp. Psychological and social findings in adolescents with phenylketonuria. Eur J Pediatr 1992; 151: 522-525.
41.
Weglage J, Funders B, Ullrich K i wsp. Psychosocial aspects in phenylketonuria. Eur J Pediatr 1996; 155: 101-104.
42.
Weglage J, Grenzebach M, Pietsch M i wsp. Behavioural and emotional problems in early-treated adolescents with phenylketonuria in comparison with diabetic patients and healthy controls. J Inherit Metab Dis 2000; 23: 487-496.
43.
Brumm VL, Bilder D, Waisbren SE. Psychiatric symptoms and disorders in phenylketonuria. Mol Genet Metab 2010; 99: 59-63.
44.
Cabalska B, Duczyńska N. Fenyloketonuria, Doniesienie I. Wczesne badania diagnostyczne. Pediatr Pol 1967; 42: 1181-1192.
45.
Cabalska B, Duczyńska N, Borzymowska J i wsp. Termination of dietary treatment in phenylketonuria. Eur J Pediatr 1977; 126: 253-262.
46.
Bosch AM, Tybout W, Van Spronsen FJ i wsp. The course of life and quality of life of early and continuously treated Dutch patients with phenylketonuria. J Inherit Metab Dis 2007; 30: 29-34.
47.
Douglas TD, Ramakrishnan U, Kable JA i wsp. Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride. Health Qual Life Outcomes 2013; 11: 218.
48.
Landolt MA, Nuoffer JM, Steinmann B i wsp. Quality of life and psychologic adjustment in children and adolescents with early treated phenylketonuria can be normal. J Pediatr 2002; 140: 516-521.
49.
Thimm E, Schmidt LE, Heldt K i wsp. Health-related quality of life in children and adolescents with phenylketonuria: unimpaired HRQoL in patients but feared school failure in parents. J Inherit Metab Dis 2013; 36: 767-772.
50.
Fidika A, Salewski C, Goldbeck L. Quality of life among parents of children with phenylketonuria (PKU). Health Qual Life Outcomes 2013; 11: 54.
51.
Choroby rzadkie w Polsce: stan obecny i perspektywy. Uczelnia Łazarskiego, 2016. http://www.lazarski.pl/pl/pobi... (dostęp: 19.03.2017).
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
